Show simple item record

dc.contributor.authorGeleta, Bekesho
dc.contributor.authorPark, Kyung Chan
dc.contributor.authorJansson, Patric J
dc.contributor.authorSahni, Sumit
dc.contributor.authorApte, Minoti
dc.contributor.authorRichardson, Des
dc.contributor.authorKovacevic, Zaklina
dc.date.accessioned2021-10-17T23:10:23Z
dc.date.available2021-10-17T23:10:23Z
dc.date.issued2021
dc.identifier.issn1743-7555en_US
dc.identifier.urihttp://hdl.handle.net/10072/409146
dc.description.abstractBackground and Aims: Pancreatic cancer (PaCa) is characterized by a dense stroma surrounding the tumor cells composed of mainly pancreatic stellate cells (PSCs), which are activated by Sonic hedgehog (SHH) produced by PaCa cells. In turn, activated PSCs release cytokines and growth factors, such as hepatocyte growth factor (HGF), insulin-like growth factor (IGF-1), and interleukin 6 (IL-6), that stimulate proliferation and metastatic ability of PaCa cells. N-myc downstream regulated gene 1 (NDRG1) is a metastasis suppressor and potent inhibitor of numerous oncogenic signaling pathways in PaCa cells. We hypothesized that targeting NDRG1 using the novel clinically trialed anticancer agent, di (2-pyridyl) ketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), may interrupt the oncogenic cross-talk between PSCs and PaCa cells. Methods: We examined the effects of NDRG1 and DpC on: (1) HGF and IGF-1 receptor activation and down-stream signaling in PaCa cells; (2) PaCa-mediated production of SHH; and (3) activation of PSCs and their ability to produce HGF, IGF-1, and IL-6. To assess the tumor–stromal interaction, we used PSC and AsPC-1 conditioned media, 3D coculture spheroids, and an orthotopic in vivo model that incorporates both PaCa cells and PSC cells. Results: We demonstrate that DpC potently inhibits the activation of HGF and IGF-1 pathways in PaCa cells, with this effect being dependent on NDRG1. DpC also inhibited SHH signaling and PSC activation, leading to reduced production of HGF, IGF, and IL-6 by these stromal cells. In vivo, DpC markedly reduced PaCa tumor growth and metastasis, being more effective than gemcitabine. Conclusion: Targeting NDRG1 with DpC can interrupt the bidirectional cross-talk between PaCa and PSCs, breaking the oncogenic cycle that promotes desmoplasia. This presents a unique and innovative opportunity to overcome the desmoplasia of PaCa and constitutes a novel approach to overcoming PaCa progression and metastasis.en_US
dc.languageEnglishen_US
dc.publisherWileyen_US
dc.publisher.urihttps://onlinelibrary.wiley.com/doi/10.1111/ajco.13651en_US
dc.relation.ispartofconferencenameSydney Cancer Conference 2021en_US
dc.relation.ispartofconferencetitleAsia-Pacific Journal of Clinical Oncologyen_US
dc.relation.ispartofdatefrom2021-09-09
dc.relation.ispartofdateto2021-09-10
dc.relation.ispartoflocationSydney, Australiaen_US
dc.relation.ispartofpagefrom13en_US
dc.relation.ispartofpageto14en_US
dc.relation.ispartofissueS5en_US
dc.relation.ispartofvolume17en_US
dc.subject.fieldofresearchOncology and carcinogenesisen_US
dc.subject.fieldofresearchcode3211en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.titleTargeting NDRG1 to inhibit bidirectional oncogenic cross-talk between pancreatic cancer and stromaen_US
dc.typeConference outputen_US
dc.type.descriptionE3 - Conferences (Extract Paper)en_US
dcterms.bibliographicCitationGeleta, B; Park, KC; Jansson, PJ; Sahni, S; Apte, M; Richardson, D; Kovacevic, Z, Targeting NDRG1 to inhibit bidirectional oncogenic cross-talk between pancreatic cancer and stroma, Asia-Pacific Journal of Clinical Oncology, 2021, 17 (S5), pp. 13-14en_US
dc.date.updated2021-10-15T01:31:32Z
gro.hasfulltextNo Full Text
gro.griffith.authorRichardson, Des R.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record